Cymabay Therapeutics Inc. (CBAY) NASDAQ
$0 - (-)
Market Cap: -
As of 03/21/24 12:00 AM EDT. Market closed.
Cymabay Therapeutics Inc. (CBAY)
NASDAQ
$0
- (-)
Market Cap: -
As of 03/21/24 12:00 AM EDT. Market closed.
Add to Portfolio
cymabay therapeutics is a clinical-stage biopharmaceutical company located in the san francisco bay area focused on developing therapies to treat metabolic diseases with high unmet medical need or serious rare and orphan diseases. we are committed to developing breakthrough medicines that improve the lives of patients and their families. cymabay was seeded with the assets from an earlier ... read more
COMPANY PROFILE
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
CEO Compensation (Base)
$451,796
CEO Compensation (Total)
$1.94M
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
CEO
Sujal Shah
CEO Compensation (Base)
$451,796
CEO Compensation (Total)
$1.94M
URL
Address
7575 Gateway Blvd Ste 110, California, Newark, 94560-1194.
PRICE CHART FOR CYMABAY THERAPEUTICS INC
From:
To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
-
Previous Close
$0
Days Range
$32.48 - $32.50
52 week range
- - -
Volume
1,000,000
Avg. Volume (30 days)
0
Market Cap
-
Dividend Yield
-
P/E
-
Shares Outstanding
114,724,381
Open
-
Previous Close
$0
Days Range
$32.48 - $32.50
52 week range
- - -
Volume
1,000,000
Avg. Volume (30 days)
0
Market Cap
-
Dividend Yield
-
P/E
-
Shares Outstanding
114,724,381
FINANCIAL STATEMENTS FOR CYMABAY THERAPEUTICS INC
LOADING...
Open in: 
Open in:
INSIDER TRANSACTIONS FOR CYMABAY THERAPEUTICS INC
| Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
| Shah Sujal | Chief Executive Officer | Mar 13, 2024 | Option Exercise | $4.72 | 139,119 | 655,959 | 406,670 | Mar 15, 2024, 04:03 PM |
| Quinlan Paul T | General Counsel | Mar 13, 2024 | Option Exercise | $7.89 | 41,824 | 329,991 | 70,262 | Mar 15, 2024, 04:02 PM |
| Dorling Janet | Director | Feb 12, 2024 | Option Exercise | $4.63 | 6,000 | 27,780 | 6,000 | Feb 14, 2024, 06:43 PM |
| Dorling Janet | Director | Feb 12, 2024 | Sale | $31.97 | 6,000 | 191,849 | 0 | Feb 14, 2024, 06:43 PM |
| McWherter Charles | President of R&D | Jan 19, 2024 | Option Exercise | $7.09 | 18,403 | 130,522 | 23,334 | Jan 22, 2024, 06:59 PM |
| McWherter Charles | President of R&D | Jan 19, 2024 | Sale | $23.67 | 18,403 | 435,645 | 15,000 | Jan 22, 2024, 06:59 PM |
| Menold Daniel | Vice President, Finance | Jan 16, 2024 | Option Exercise | $4.05 | 10,000 | 40,500 | 10,000 | Jan 16, 2024, 07:07 PM |
| Menold Daniel | Vice President, Finance | Jan 16, 2024 | Sale | $23.58 | 10,000 | 235,806 | 0 | Jan 16, 2024, 07:07 PM |
| Quinlan Paul T | General Counsel | Jan 16, 2024 | Option Exercise | $2.94 | 5,000 | 14,700 | 5,000 | Jan 16, 2024, 07:07 PM |
| Quinlan Paul T | General Counsel | Jan 16, 2024 | Sale | $23.58 | 5,000 | 117,898 | 0 | Jan 16, 2024, 07:07 PM |
| Dorling Janet | Director | Jan 10, 2024 | Option Exercise | $4.63 | 6,000 | 27,780 | 6,000 | Jan 10, 2024, 08:35 PM |
| Dorling Janet | Director | Jan 10, 2024 | Sale | $23.86 | 6,000 | 143,144 | 0 | Jan 10, 2024, 08:35 PM |
| McWherter Charles | President of R&D | Dec 18, 2023 | Option Exercise | $5.00 | 11,332 | 56,660 | 21,504 | Dec 18, 2023, 08:04 PM |
| McWherter Charles | President of R&D | Dec 18, 2023 | Sale | $21.48 | 11,332 | 243,441 | 15,000 | Dec 18, 2023, 08:04 PM |
| Menold Daniel | Vice President, Finance | Dec 15, 2023 | Option Exercise | $6.39 | 21,497 | 137,420 | 11,497 | Dec 15, 2023, 04:38 PM |
| Menold Daniel | Vice President, Finance | Dec 15, 2023 | Sale | $21.99 | 21,497 | 472,646 | 0 | Dec 15, 2023, 04:38 PM |
| Quinlan Paul T | General Counsel | Dec 15, 2023 | Option Exercise | $2.94 | 5,000 | 14,700 | 5,000 | Dec 15, 2023, 04:35 PM |
| Quinlan Paul T | General Counsel | Dec 15, 2023 | Sale | $21.98 | 5,000 | 109,902 | 0 | Dec 15, 2023, 04:35 PM |
| Shah Sujal | Chief Executive Officer | Dec 11, 2023 | Option Exercise | $5.00 | 64,865 | 324,325 | 235,276 | Dec 11, 2023, 07:03 PM |
| Shah Sujal | Chief Executive Officer | Dec 11, 2023 | Sale | $20.00 | 64,865 | 1,297,170 | 171,301 | Dec 11, 2023, 07:03 PM |
| Dorling Janet | Director | Dec 11, 2023 | Option Exercise | $4.63 | 6,000 | 27,780 | 6,000 | Dec 11, 2023, 07:01 PM |
| Dorling Janet | Director | Dec 11, 2023 | Sale | $20.07 | 6,000 | 120,422 | 0 | Dec 11, 2023, 07:01 PM |
| McWherter Charles | President of R&D | Nov 17, 2023 | Option Exercise | $5.00 | 11,342 | 56,710 | 26,342 | Nov 17, 2023, 05:58 PM |
| McWherter Charles | President of R&D | Nov 17, 2023 | Sale | $18.28 | 11,342 | 207,293 | 15,000 | Nov 17, 2023, 05:58 PM |
| Menold Daniel | Vice President, Finance | Nov 15, 2023 | Option Exercise | $3.45 | 17,500 | 60,375 | 17,500 | Nov 17, 2023, 05:57 PM |
| Quinlan Paul T | General Counsel | Nov 15, 2023 | Option Exercise | $2.94 | 5,000 | 14,700 | 5,000 | Nov 17, 2023, 05:57 PM |
| Quinlan Paul T | General Counsel | Nov 15, 2023 | Sale | $17.38 | 5,000 | 86,889 | 0 | Nov 17, 2023, 05:57 PM |
| Shah Sujal | Chief Executive Officer | Nov 13, 2023 | Option Exercise | $5.00 | 64,863 | 324,315 | 215,309 | Nov 14, 2023, 06:00 PM |
| Shah Sujal | Chief Executive Officer | Nov 13, 2023 | Sale | $15.89 | 64,863 | 1,030,660 | 171,301 | Nov 14, 2023, 06:00 PM |
| Dorling Janet | Director | Nov 10, 2023 | Option Exercise | $4.63 | 7,000 | 32,410 | 7,000 | Nov 14, 2023, 05:56 PM |
| Dorling Janet | Director | Nov 10, 2023 | Sale | $15.24 | 7,000 | 106,700 | 0 | Nov 14, 2023, 05:56 PM |
| McWherter Charles | President of R&D | Oct 18, 2023 | Option Exercise | $5.00 | 21,743 | 108,715 | 36,743 | Oct 18, 2023, 06:22 PM |
| McWherter Charles | President of R&D | Oct 18, 2023 | Sale | $14.07 | 21,743 | 305,941 | 15,000 | Oct 18, 2023, 06:22 PM |
| Menold Daniel | Vice President, Finance | Oct 16, 2023 | Option Exercise | $3.45 | 17,500 | 60,375 | 17,500 | Oct 18, 2023, 06:22 PM |
| Quinlan Paul T | General Counsel | Oct 16, 2023 | Option Exercise | $2.94 | 5,000 | 14,700 | 5,000 | Oct 18, 2023, 06:21 PM |
| Quinlan Paul T | General Counsel | Oct 16, 2023 | Sale | $13.76 | 5,000 | 68,798 | 0 | Oct 18, 2023, 06:21 PM |
| Shah Sujal | Chief Executive Officer | Oct 09, 2023 | Option Exercise | $5.00 | 64,861 | 324,305 | 236,162 | Oct 10, 2023, 05:04 PM |
| Shah Sujal | Chief Executive Officer | Oct 09, 2023 | Sale | $14.20 | 64,861 | 921,286 | 171,301 | Oct 10, 2023, 05:04 PM |
| EMSTER KURT VON | Director | Sep 29, 2023 | Option Exercise | $5.00 | 15,921 | 79,605 | 105,921 | Sep 29, 2023, 05:54 PM |
| EMSTER KURT VON | Director | Sep 29, 2023 | Sale | $15.68 | 15,921 | 249,675 | 90,000 | Sep 29, 2023, 05:54 PM |
| McWherter Charles | President of R&D | Sep 18, 2023 | Option Exercise | $5.00 | 21,746 | 108,730 | 36,746 | Sep 19, 2023, 05:27 PM |
| McWherter Charles | President of R&D | Sep 18, 2023 | Sale | $16.22 | 21,746 | 352,733 | 15,000 | Sep 19, 2023, 05:27 PM |
| Menold Daniel | Vice President, Finance | Sep 15, 2023 | Option Exercise | $1.73 | 16,545 | 28,612 | 15,000 | Sep 19, 2023, 05:25 PM |
| Quinlan Paul T | General Counsel | Sep 15, 2023 | Option Exercise | $2.94 | 53,000 | 155,820 | 24,000 | Sep 19, 2023, 05:23 PM |
| Quinlan Paul T | General Counsel | Sep 15, 2023 | Sale | $16.87 | 53,000 | 894,141 | 0 | Sep 19, 2023, 05:23 PM |
| McWherter Charles | President of R&D | Aug 18, 2023 | Option Exercise | $5.00 | 21,746 | 108,730 | 36,746 | Aug 18, 2023, 07:03 PM |
| McWherter Charles | President of R&D | Aug 18, 2023 | Sale | $11.47 | 21,746 | 249,359 | 15,000 | Aug 18, 2023, 07:03 PM |
| Menold Daniel | Vice President, Finance | Aug 15, 2023 | Option Exercise | $5.10 | 15,500 | 79,010 | 8,500 | Aug 16, 2023, 04:59 PM |
| Quinlan Paul T | General Counsel | Aug 15, 2023 | Option Exercise | $2.94 | 5,000 | 14,700 | 5,000 | Aug 16, 2023, 04:57 PM |
| Quinlan Paul T | General Counsel | Aug 15, 2023 | Sale | $11.91 | 5,000 | 59,550 | 0 | Aug 16, 2023, 04:57 PM |
| Menold Daniel | Vice President, Finance | Aug 09, 2023 | Option Exercise | $5.00 | 20,945 | 104,725 | 20,945 | Aug 11, 2023, 06:26 PM |
| Menold Daniel | Vice President, Finance | Aug 09, 2023 | Sale | $12.35 | 20,945 | 258,744 | 0 | Aug 11, 2023, 06:26 PM |
| McWherter Charles | President of R&D | Jul 18, 2023 | Option Exercise | $5.00 | 21,749 | 108,745 | 36,749 | Jul 19, 2023, 06:05 PM |
| McWherter Charles | President of R&D | Jul 18, 2023 | Sale | $11.43 | 21,749 | 248,519 | 15,000 | Jul 19, 2023, 06:05 PM |
| Quinlan Paul T | General Counsel | Jul 14, 2023 | Option Exercise | $2.94 | 5,000 | 14,700 | 5,000 | Jul 14, 2023, 06:52 PM |
| Quinlan Paul T | General Counsel | Jul 14, 2023 | Sale | $11.81 | 5,000 | 59,050 | 0 | Jul 14, 2023, 06:52 PM |
| Quinlan Paul T | General Counsel | Jun 30, 2023 | Option Exercise | $2.94 | 5,000 | 14,700 | 5,000 | Jun 30, 2023, 04:51 PM |
| Quinlan Paul T | General Counsel | Jun 30, 2023 | Sale | $10.05 | 5,000 | 50,250 | 0 | Jun 30, 2023, 04:51 PM |
| McWherter Charles | President of R&D | Jun 20, 2023 | Option Exercise | $5.00 | 21,749 | 108,745 | 36,749 | Jun 21, 2023, 06:46 PM |
| McWherter Charles | President of R&D | Jun 20, 2023 | Sale | $8.16 | 21,749 | 177,383 | 15,000 | Jun 21, 2023, 06:46 PM |
| McWherter Charles | President of R&D | May 18, 2023 | Option Exercise | $5.00 | 21,749 | 108,745 | 36,749 | May 19, 2023, 06:00 PM |
| McWherter Charles | President of R&D | May 18, 2023 | Sale | $9.08 | 21,749 | 197,387 | 15,000 | May 19, 2023, 06:00 PM |
| Quinlan Paul T | General Counsel | May 15, 2023 | Option Exercise | $2.94 | 5,000 | 14,700 | 5,000 | May 17, 2023, 07:11 PM |
| Quinlan Paul T | General Counsel | May 15, 2023 | Sale | $10.37 | 5,000 | 51,831 | 0 | May 17, 2023, 07:11 PM |
| KIM DENNIS D | Chief Medical Officer | Apr 17, 2023 | Option Exercise | $4.37 | 112,219 | 490,397 | 132,219 | Apr 17, 2023, 07:24 PM |
| KIM DENNIS D | Chief Medical Officer | Apr 13, 2023 | Option Exercise | $4.37 | 7,781 | 34,003 | 27,781 | Apr 17, 2023, 07:24 PM |
| KIM DENNIS D | Chief Medical Officer | Apr 13, 2023 | Sale | $8.98 | 7,781 | 69,880 | 20,000 | Apr 17, 2023, 07:24 PM |
| KIM DENNIS D | Chief Medical Officer | Apr 17, 2023 | Sale | $9.54 | 112,219 | 1,070,536 | 20,000 | Apr 17, 2023, 07:24 PM |
| KIM DENNIS D | Chief Medical Officer | Mar 28, 2023 | Option Exercise | $4.37 | 100 | 437 | 20,100 | Mar 30, 2023, 05:39 PM |
| KIM DENNIS D | Chief Medical Officer | Mar 28, 2023 | Sale | $8.98 | 100 | 898 | 20,000 | Mar 30, 2023, 05:39 PM |
| Shah Sujal | Chief Executive Officer | Jun 06, 2022 | Buy | $1.95 | 51,301 | 100,037 | 171,301 | Jun 07, 2022, 08:14 AM |
| KIM DENNIS D | Chief Medical Officer | Jan 19, 2022 | Buy | $3.04 | 20,000 | 60,800 | 20,000 | Jan 20, 2022, 04:35 PM |
| Shah Sujal | Chief Executive Officer | Oct 10, 2019 | Buy | $4.30 | 5,000 | 21,500 | 120,000 | Oct 15, 2019, 08:20 AM |
| Shah Sujal | Chief Executive Officer | Sep 23, 2019 | Buy | $5.55 | 3,100 | 17,205 | 115,000 | Sep 24, 2019, 08:56 AM |
| Shah Sujal | Chief Executive Officer | Sep 20, 2019 | Buy | $5.50 | 1,900 | 10,450 | 111,900 | Sep 24, 2019, 08:56 AM |
| GOLDFISCHER CARL | Director | Feb 07, 2019 | Option Exercise | $5.40 | 11,675 | 63,045 | 11,675 | Feb 08, 2019, 08:21 PM |
| GOLDFISCHER CARL | Director | Feb 07, 2019 | Sale | $9.02 | 11,675 | 105,328 | 0 | Feb 08, 2019, 08:21 PM |
| Shah Sujal | Chief Executive Officer | Dec 21, 2018 | Buy | $6.54 | 10,000 | 65,399 | 110,000 | Dec 21, 2018, 05:11 PM |
| EMSTER KURT VON | Director | Dec 18, 2018 | Sale | $7.43 | 53,492 | 397,365 | 131,036 | Dec 19, 2018, 04:18 PM |
| EMSTER KURT VON | Director | Dec 17, 2018 | Sale | $8.17 | 88,889 | 726,223 | 184,528 | Dec 19, 2018, 04:18 PM |
| Shah Sujal | Chief Executive Officer | Oct 15, 2018 | Buy | $9.90 | 5,000 | 49,500 | 100,000 | Oct 16, 2018, 06:21 AM |
| Menold Daniel | Vice President, Finance | Aug 29, 2018 | Option Exercise | $5.00 | 5,000 | 25,000 | 5,000 | Aug 31, 2018, 07:24 PM |
| Menold Daniel | Vice President, Finance | Aug 29, 2018 | Sale | $13.00 | 5,000 | 65,000 | 0 | Aug 31, 2018, 07:24 PM |
| Shah Sujal | Chief Executive Officer | Jul 27, 2018 | Buy | $10.90 | 5,000 | 54,500 | 95,000 | Jul 30, 2018, 06:05 AM |
| EMSTER KURT VON | Director | Jun 05, 2018 | Sale | $12.51 | 920 | 11,509 | 18,316 | Jun 11, 2018, 08:42 AM |
| EMSTER KURT VON | Director | Jun 05, 2018 | Option Exercise | $5.75 | 2,000 | 11,500 | 19,236 | Jun 11, 2018, 08:42 AM |
| EMSTER KURT VON | Director | Jun 05, 2018 | Sale | $12.51 | 920 | 11,509 | 18,316 | Jun 07, 2018, 07:30 PM |
| EMSTER KURT VON | Director | Jun 05, 2018 | Option Exercise | $5.75 | 2,000 | 11,500 | 19,236 | Jun 07, 2018, 07:30 PM |
| Shah Sujal | Chief Executive Officer | May 11, 2018 | Buy | $10.65 | 5,000 | 53,250 | 90,000 | May 15, 2018, 08:08 AM |
| GOLDFISCHER CARL | Director | Mar 22, 2018 | Option Exercise | $5.19 | 15,000 | 77,830 | 15,000 | Mar 23, 2018, 04:56 PM |
| GOLDFISCHER CARL | Director | Mar 22, 2018 | Sale | $13.02 | 15,000 | 195,375 | 0 | Mar 23, 2018, 04:56 PM |
| EMSTER KURT VON | Director | Mar 05, 2018 | Sale | $15.51 | 13,353 | 207,105 | 273,417 | Mar 07, 2018, 04:19 PM |
| EMSTER KURT VON | Director | Feb 15, 2018 | Sale | $14.49 | 68,712 | 995,637 | 286,770 | Feb 20, 2018, 04:08 PM |
| EMSTER KURT VON | Director | Feb 14, 2018 | Sale | $13.69 | 162,979 | 2,231,182 | 355,482 | Feb 16, 2018, 02:44 PM |
| EMSTER KURT VON | Director | Feb 14, 2018 | Sale | $16.69 | 162,979 | 2,720,120 | 355,482 | Feb 15, 2018, 04:12 PM |
| EMSTER KURT VON | Director | Feb 13, 2018 | Sale | $13.51 | 55,078 | 744,104 | 518,461 | Feb 15, 2018, 04:12 PM |
| EMSTER KURT VON | Director | Jul 19, 2017 | Buy | $6.50 | 153,846 | 999,999 | 1,753,846 | Feb 12, 2018, 04:09 PM |
| EMSTER KURT VON | Director | Feb 07, 2018 | Sale | $12.35 | 40,763 | 503,423 | 419,693 | Feb 09, 2018, 04:17 PM |
| EMSTER KURT VON | Director | Feb 05, 2018 | Sale | $12.14 | 18,831 | 228,608 | 460,456 | Feb 07, 2018, 04:20 PM |
| EMSTER KURT VON | Director | Feb 02, 2018 | Sale | $12.11 | 2,000 | 24,220 | 479,287 | Feb 05, 2018, 04:07 PM |
| EMSTER KURT VON | Director | Feb 01, 2018 | Sale | $12.15 | 88,098 | 1,070,391 | 481,287 | Feb 05, 2018, 04:07 PM |
| EMSTER KURT VON | Director | Jan 31, 2018 | Sale | $12.23 | 12,300 | 150,429 | 569,385 | Feb 01, 2018, 04:29 PM |
| EMSTER KURT VON | Director | Jan 30, 2018 | Sale | $12.22 | 85,339 | 1,042,843 | 581,685 | Feb 01, 2018, 04:29 PM |
| EMSTER KURT VON | Director | Jan 25, 2018 | Sale | $12.18 | 39,438 | 480,355 | 667,024 | Jan 26, 2018, 08:40 PM |
| EMSTER KURT VON | Director | Jan 22, 2018 | Sale | $10.40 | 138,253 | 1,437,831 | 706,462 | Jan 24, 2018, 04:02 PM |
| EMSTER KURT VON | Director | Jan 19, 2018 | Sale | $10.25 | 130,584 | 1,338,486 | 844,715 | Jan 22, 2018, 05:26 PM |
| EMSTER KURT VON | Director | Jan 18, 2018 | Sale | $10.21 | 13,632 | 139,183 | 975,299 | Jan 22, 2018, 05:26 PM |
| EMSTER KURT VON | Director | Jan 05, 2018 | Sale | $10.21 | 4,300 | 43,903 | 988,931 | Jan 09, 2018, 04:34 PM |
| EMSTER KURT VON | Director | Dec 22, 2017 | Sale | $9.41 | 173,192 | 1,629,304 | 993,231 | Dec 27, 2017, 04:08 PM |
| EMSTER KURT VON | Director | Nov 10, 2017 | Sale | $9.26 | 50,048 | 463,379 | 1,166,423 | Nov 14, 2017, 05:48 PM |
| GOLDFISCHER CARL | Director | Nov 02, 2017 | Option Exercise | $2.35 | 18,000 | 42,210 | 18,000 | Nov 06, 2017, 08:45 PM |
| GOLDFISCHER CARL | Director | Nov 02, 2017 | Sale | $8.66 | 18,000 | 155,880 | 0 | Nov 06, 2017, 08:45 PM |
| McWherter Charles | SVP & Chief Scientific Officer | Nov 02, 2017 | Buy | $8.67 | 5,000 | 43,341 | 15,000 | Nov 06, 2017, 08:43 PM |
| EMSTER KURT VON | Director | Nov 01, 2017 | Sale | $9.25 | 4,320 | 39,979 | 1,216,471 | Nov 03, 2017, 04:52 PM |
| EMSTER KURT VON | Director | Oct 31, 2017 | Sale | $9.27 | 52,573 | 487,352 | 1,220,791 | Nov 01, 2017, 04:39 PM |
| EMSTER KURT VON | Director | Oct 30, 2017 | Sale | $9.26 | 6,636 | 61,449 | 1,273,364 | Nov 01, 2017, 04:39 PM |
| EMSTER KURT VON | Director | Oct 02, 2017 | Sale | $7.93 | 37,936 | 300,832 | 1,350,940 | Oct 04, 2017, 04:02 PM |
| EMSTER KURT VON | Director | Oct 03, 2017 | Sale | $7.81 | 70,940 | 554,041 | 1,280,000 | Oct 04, 2017, 04:02 PM |
| EMSTER KURT VON | Director | Sep 29, 2017 | Sale | $8.04 | 120,735 | 970,709 | 1,388,876 | Oct 02, 2017, 05:20 PM |
| EMSTER KURT VON | Director | Sep 28, 2017 | Sale | $8.15 | 90,389 | 736,670 | 1,509,611 | Oct 02, 2017, 05:20 PM |
| Wills Robert James | Director | Aug 01, 2017 | Buy | $6.84 | 5,000 | 34,221 | 30,000 | Aug 02, 2017, 08:21 AM |
| McWherter Charles | SVP & Chief Scientific Officer | Jul 20, 2017 | Buy | $7.43 | 5,000 | 37,137 | 10,000 | Jul 24, 2017, 06:19 AM |
| Shah Sujal | Interim President & CEO | Jul 20, 2017 | Buy | $7.34 | 10,000 | 73,400 | 85,000 | Jul 24, 2017, 06:15 AM |
| Wills Robert James | Director | Sep 06, 2016 | Buy | $2.43 | 25,000 | 60,857 | 25,000 | Sep 09, 2016, 08:05 AM |
| OMara Patrick J. | VP, Business Development | Apr 15, 2016 | Buy | $1.64 | 5,000 | 8,200 | 5,022 | Apr 19, 2016, 07:56 AM |
| McWherter Charles | Sr. Vice President | Apr 15, 2016 | Buy | $1.68 | 3,000 | 5,040 | 5,000 | Apr 19, 2016, 07:54 AM |
| Shah Sujal | Chief Financial Officer | Apr 05, 2016 | Buy | $1.39 | 33,000 | 45,870 | 75,000 | Apr 06, 2016, 04:21 PM |
| Shah Sujal | Chief Financial Officer | Apr 04, 2016 | Buy | $1.39 | 22,000 | 30,580 | 42,000 | Apr 06, 2016, 04:21 PM |
| GOLDFISCHER CARL | Director | Sep 09, 2015 | Sale | $2.76 | 13 | 36 | 28 | Sep 11, 2015, 05:28 PM |
| GOLDFISCHER CARL | Director | Sep 11, 2015 | Sale | $2.77 | 13 | 36 | 0 | Sep 11, 2015, 05:28 PM |
| GOLDFISCHER CARL | Director | Sep 10, 2015 | Sale | $2.71 | 1,011 | 2,740 | 948 | Sep 11, 2015, 05:28 PM |
| GOLDFISCHER CARL | Director | Sep 10, 2015 | Sale | $2.71 | 15,474 | 41,935 | 14,506 | Sep 11, 2015, 05:28 PM |
| GOLDFISCHER CARL | Director | Sep 10, 2015 | Sale | $2.71 | 15 | 41 | 13 | Sep 11, 2015, 05:28 PM |
| GOLDFISCHER CARL | Director | Sep 09, 2015 | Sale | $2.76 | 905 | 2,498 | 1,959 | Sep 11, 2015, 05:28 PM |
| GOLDFISCHER CARL | Director | Sep 11, 2015 | Sale | $2.76 | 948 | 2,616 | 0 | Sep 11, 2015, 05:28 PM |
| GOLDFISCHER CARL | Director | Sep 09, 2015 | Sale | $2.76 | 13,844 | 38,209 | 29,980 | Sep 11, 2015, 05:28 PM |
| GOLDFISCHER CARL | Director | Sep 11, 2015 | Sale | $2.76 | 14,506 | 40,037 | 0 | Sep 11, 2015, 05:28 PM |
| von Emster Kurt | Director | Aug 14, 2015 | Buy | $2.70 | 58,641 | 158,313 | 90,000 | Aug 17, 2015, 05:27 PM |
| von Emster Kurt | Director | Aug 13, 2015 | Buy | $2.68 | 31,359 | 84,161 | 31,359 | Aug 17, 2015, 05:27 PM |
| von Emster Kurt | Director | Jul 20, 2015 | Buy | $2.81 | 1,600,000 | 4,496,000 | 1,600,000 | Jul 21, 2015, 06:35 PM |
| McWherter Charles | Sr. Vice President | May 15, 2015 | Buy | $3.16 | 2,000 | 6,318 | 2,000 | May 19, 2015, 07:46 PM |
| Van Wart Harold | President and CEO | May 18, 2015 | Buy | $3.34 | 7,500 | 25,039 | 7,958 | May 19, 2015, 07:44 PM |
| Shah Sujal | Chief Financial Officer | May 18, 2015 | Buy | $3.40 | 10,000 | 34,000 | 20,000 | May 19, 2015, 07:41 PM |
Load More Insider Transactions
Buy
Sale
Option Exercise
| Owner | Relationship | Date | Value($) |
| Shah Sujal | Chief Executive Officer | 03/13/2024 | 655,959 |
| Quinlan Paul T | General Counsel | 03/13/2024 | 329,991 |
| Dorling Janet | Director | 02/12/2024 | 27,780 |
| Dorling Janet | Director | 02/12/2024 | 191,849 |
| McWherter Charles | President of R&D | 01/19/2024 | 130,522 |
| McWherter Charles | President of R&D | 01/19/2024 | 435,645 |
| Menold Daniel | Vice President, Finance | 01/16/2024 | 40,500 |
| Menold Daniel | Vice President, Finance | 01/16/2024 | 235,806 |
| Quinlan Paul T | General Counsel | 01/16/2024 | 14,700 |
| Quinlan Paul T | General Counsel | 01/16/2024 | 117,898 |
| Dorling Janet | Director | 01/10/2024 | 27,780 |
| Dorling Janet | Director | 01/10/2024 | 143,144 |
| McWherter Charles | President of R&D | 12/18/2023 | 56,660 |
| McWherter Charles | President of R&D | 12/18/2023 | 243,441 |
| Menold Daniel | Vice President, Finance | 12/15/2023 | 137,420 |
| Menold Daniel | Vice President, Finance | 12/15/2023 | 472,646 |
| Quinlan Paul T | General Counsel | 12/15/2023 | 14,700 |
| Quinlan Paul T | General Counsel | 12/15/2023 | 109,902 |
| Shah Sujal | Chief Executive Officer | 12/11/2023 | 324,325 |
| Shah Sujal | Chief Executive Officer | 12/11/2023 | 1,297,170 |
| Dorling Janet | Director | 12/11/2023 | 27,780 |
| Dorling Janet | Director | 12/11/2023 | 120,422 |
| McWherter Charles | President of R&D | 11/17/2023 | 56,710 |
| McWherter Charles | President of R&D | 11/17/2023 | 207,293 |
| Menold Daniel | Vice President, Finance | 11/15/2023 | 60,375 |
| Quinlan Paul T | General Counsel | 11/15/2023 | 14,700 |
| Quinlan Paul T | General Counsel | 11/15/2023 | 86,889 |
| Shah Sujal | Chief Executive Officer | 11/13/2023 | 324,315 |
| Shah Sujal | Chief Executive Officer | 11/13/2023 | 1,030,660 |
| Dorling Janet | Director | 11/10/2023 | 32,410 |
| Dorling Janet | Director | 11/10/2023 | 106,700 |
| McWherter Charles | President of R&D | 10/18/2023 | 108,715 |
| McWherter Charles | President of R&D | 10/18/2023 | 305,941 |
| Menold Daniel | Vice President, Finance | 10/16/2023 | 60,375 |
| Quinlan Paul T | General Counsel | 10/16/2023 | 14,700 |
| Quinlan Paul T | General Counsel | 10/16/2023 | 68,798 |
| Shah Sujal | Chief Executive Officer | 10/09/2023 | 324,305 |
| Shah Sujal | Chief Executive Officer | 10/09/2023 | 921,286 |
| EMSTER KURT VON | Director | 09/29/2023 | 79,605 |
| EMSTER KURT VON | Director | 09/29/2023 | 249,675 |
| McWherter Charles | President of R&D | 09/18/2023 | 108,730 |
| McWherter Charles | President of R&D | 09/18/2023 | 352,733 |
| Menold Daniel | Vice President, Finance | 09/15/2023 | 28,612 |
| Quinlan Paul T | General Counsel | 09/15/2023 | 155,820 |
| Quinlan Paul T | General Counsel | 09/15/2023 | 894,141 |
| McWherter Charles | President of R&D | 08/18/2023 | 108,730 |
| McWherter Charles | President of R&D | 08/18/2023 | 249,359 |
| Menold Daniel | Vice President, Finance | 08/15/2023 | 79,010 |
| Quinlan Paul T | General Counsel | 08/15/2023 | 14,700 |
| Quinlan Paul T | General Counsel | 08/15/2023 | 59,550 |
| Menold Daniel | Vice President, Finance | 08/09/2023 | 104,725 |
| Menold Daniel | Vice President, Finance | 08/09/2023 | 258,744 |
| McWherter Charles | President of R&D | 07/18/2023 | 108,745 |
| McWherter Charles | President of R&D | 07/18/2023 | 248,519 |
| Quinlan Paul T | General Counsel | 07/14/2023 | 14,700 |
| Quinlan Paul T | General Counsel | 07/14/2023 | 59,050 |
| Quinlan Paul T | General Counsel | 06/30/2023 | 14,700 |
| Quinlan Paul T | General Counsel | 06/30/2023 | 50,250 |
| McWherter Charles | President of R&D | 06/20/2023 | 108,745 |
| McWherter Charles | President of R&D | 06/20/2023 | 177,383 |
| McWherter Charles | President of R&D | 05/18/2023 | 108,745 |
| McWherter Charles | President of R&D | 05/18/2023 | 197,387 |
| Quinlan Paul T | General Counsel | 05/15/2023 | 14,700 |
| Quinlan Paul T | General Counsel | 05/15/2023 | 51,831 |
| KIM DENNIS D | Chief Medical Officer | 04/17/2023 | 490,397 |
| KIM DENNIS D | Chief Medical Officer | 04/13/2023 | 34,003 |
| KIM DENNIS D | Chief Medical Officer | 04/13/2023 | 69,880 |
| KIM DENNIS D | Chief Medical Officer | 04/17/2023 | 1,070,536 |
| KIM DENNIS D | Chief Medical Officer | 03/28/2023 | 437 |
| KIM DENNIS D | Chief Medical Officer | 03/28/2023 | 898 |
| Shah Sujal | Chief Executive Officer | 06/06/2022 | 100,037 |
| KIM DENNIS D | Chief Medical Officer | 01/19/2022 | 60,800 |
| Shah Sujal | Chief Executive Officer | 10/10/2019 | 21,500 |
| Shah Sujal | Chief Executive Officer | 09/23/2019 | 17,205 |
| Shah Sujal | Chief Executive Officer | 09/20/2019 | 10,450 |
| GOLDFISCHER CARL | Director | 02/07/2019 | 63,045 |
| GOLDFISCHER CARL | Director | 02/07/2019 | 105,328 |
| Shah Sujal | Chief Executive Officer | 12/21/2018 | 65,399 |
| EMSTER KURT VON | Director | 12/18/2018 | 397,365 |
| EMSTER KURT VON | Director | 12/17/2018 | 726,223 |
| Shah Sujal | Chief Executive Officer | 10/15/2018 | 49,500 |
| Menold Daniel | Vice President, Finance | 08/29/2018 | 25,000 |
| Menold Daniel | Vice President, Finance | 08/29/2018 | 65,000 |
| Shah Sujal | Chief Executive Officer | 07/27/2018 | 54,500 |
| EMSTER KURT VON | Director | 06/05/2018 | 11,509 |
| EMSTER KURT VON | Director | 06/05/2018 | 11,500 |
| EMSTER KURT VON | Director | 06/05/2018 | 11,509 |
| EMSTER KURT VON | Director | 06/05/2018 | 11,500 |
| Shah Sujal | Chief Executive Officer | 05/11/2018 | 53,250 |
| GOLDFISCHER CARL | Director | 03/22/2018 | 77,830 |
| GOLDFISCHER CARL | Director | 03/22/2018 | 195,375 |
| EMSTER KURT VON | Director | 03/05/2018 | 207,105 |
| EMSTER KURT VON | Director | 02/15/2018 | 995,637 |
| EMSTER KURT VON | Director | 02/14/2018 | 2,231,182 |
| EMSTER KURT VON | Director | 02/14/2018 | 2,720,120 |
| EMSTER KURT VON | Director | 02/13/2018 | 744,104 |
| EMSTER KURT VON | Director | 07/19/2017 | 999,999 |
| EMSTER KURT VON | Director | 02/07/2018 | 503,423 |
| EMSTER KURT VON | Director | 02/05/2018 | 228,608 |
| EMSTER KURT VON | Director | 02/02/2018 | 24,220 |
| EMSTER KURT VON | Director | 02/01/2018 | 1,070,391 |
| EMSTER KURT VON | Director | 01/31/2018 | 150,429 |
| EMSTER KURT VON | Director | 01/30/2018 | 1,042,843 |
| EMSTER KURT VON | Director | 01/25/2018 | 480,355 |
| EMSTER KURT VON | Director | 01/22/2018 | 1,437,831 |
| EMSTER KURT VON | Director | 01/19/2018 | 1,338,486 |
| EMSTER KURT VON | Director | 01/18/2018 | 139,183 |
| EMSTER KURT VON | Director | 01/05/2018 | 43,903 |
| EMSTER KURT VON | Director | 12/22/2017 | 1,629,304 |
| EMSTER KURT VON | Director | 11/10/2017 | 463,379 |
| GOLDFISCHER CARL | Director | 11/02/2017 | 42,210 |
| GOLDFISCHER CARL | Director | 11/02/2017 | 155,880 |
| McWherter Charles | SVP & Chief Scientific Officer | 11/02/2017 | 43,341 |
| EMSTER KURT VON | Director | 11/01/2017 | 39,979 |
| EMSTER KURT VON | Director | 10/31/2017 | 487,352 |
| EMSTER KURT VON | Director | 10/30/2017 | 61,449 |
| EMSTER KURT VON | Director | 10/02/2017 | 300,832 |
| EMSTER KURT VON | Director | 10/03/2017 | 554,041 |
| EMSTER KURT VON | Director | 09/29/2017 | 970,709 |
| EMSTER KURT VON | Director | 09/28/2017 | 736,670 |
| Wills Robert James | Director | 08/01/2017 | 34,221 |
| McWherter Charles | SVP & Chief Scientific Officer | 07/20/2017 | 37,137 |
| Shah Sujal | Interim President & CEO | 07/20/2017 | 73,400 |
| Wills Robert James | Director | 09/06/2016 | 60,857 |
| OMara Patrick J. | VP, Business Development | 04/15/2016 | 8,200 |
| McWherter Charles | Sr. Vice President | 04/15/2016 | 5,040 |
| Shah Sujal | Chief Financial Officer | 04/05/2016 | 45,870 |
| Shah Sujal | Chief Financial Officer | 04/04/2016 | 30,580 |
| GOLDFISCHER CARL | Director | 09/09/2015 | 36 |
| GOLDFISCHER CARL | Director | 09/11/2015 | 36 |
| GOLDFISCHER CARL | Director | 09/10/2015 | 2,740 |
| GOLDFISCHER CARL | Director | 09/10/2015 | 41,935 |
| GOLDFISCHER CARL | Director | 09/10/2015 | 41 |
| GOLDFISCHER CARL | Director | 09/09/2015 | 2,498 |
| GOLDFISCHER CARL | Director | 09/11/2015 | 2,616 |
| GOLDFISCHER CARL | Director | 09/09/2015 | 38,209 |
| GOLDFISCHER CARL | Director | 09/11/2015 | 40,037 |
| von Emster Kurt | Director | 08/14/2015 | 158,313 |
| von Emster Kurt | Director | 08/13/2015 | 84,161 |
| von Emster Kurt | Director | 07/20/2015 | 4,496,000 |
| McWherter Charles | Sr. Vice President | 05/15/2015 | 6,318 |
| Van Wart Harold | President and CEO | 05/18/2015 | 25,039 |
| Shah Sujal | Chief Financial Officer | 05/18/2015 | 34,000 |
Load More Insider Transactions
FUNDS WITH A POSITION IN CYMABAY THERAPEUTICS INC
| Fund | # Shares Owned | % of Portfolio | % Change | Investing Style |
|---|---|---|---|---|
| BLACKROCK INC. | 9,610,239 | 0.00579% | 23.33% | Other |
| RA CAPITAL MANAGEMENT, L.P. | 6,940,000 | 2.56% | No change | Other |
| HOLOCENE ADVISORS, LP | 2,993,945 | 0.28% | -3.97% | Growth At A Reasonable Price |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 2,628,000 | 0.13% | -36.29% | Other |
| GEODE CAPITAL MANAGEMENT, LLC | 2,380,105 | 0.00588% | 14.67% | Other |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 841,677 | 0.24% | New | Growth |
| D. E. SHAW & CO., INC. | 636,897 | 0.01% | -20.19% | Other |
| RENAISSANCE TECHNOLOGIES LLC | 159,950 | 0.00585% | 40.99% | Other |
| D. E. SHAW & CO., INC. | 150,000 (Call) | 0.0031% | New | Other |
| ALPS ADVISORS INC | 75,374 | 0.01% | 4.02% | Other |
| UBS OCONNOR LLC | 50,000 (Put) | 0.00135% | -44.44% | Value |
| AQR CAPITAL MANAGEMENT LLC | 22,270 | 0.00099% | -30.64% | Other |
| GOTHAM ASSET MANAGEMENT, LLC | 19,081 | 0.00836% | -52.84% | Other |
CHANGE IN SHARES OUTSTANDING FOR CYMABAY THERAPEUTICS INC
STOCK BUYBACKS FOR CYMABAY THERAPEUTICS INC
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
Load More
Period of Report: 12/31/2023
10-K/10-Q Filings: View
Previous Period
% Change in Shares
Quarter
09/30/2023
12.46%
1Q
06/30/2023
16.39%
2Q
03/31/2023
21.35%
3Q
12/31/2022
35.40%
4Q
09/30/2022
35.41%
5Q
06/30/2022
35.41%
6Q
03/31/2022
35.41%
7Q
12/31/2021
53.87%
8Q
09/30/2021
72.25%
9Q
06/30/2021
72.34%
10Q
03/31/2021
72.44%
11Q
12/31/2020
72.51%
12Q
09/30/2020
72.59%
13Q
06/30/2020
72.60%
14Q
03/31/2020
72.60%
15Q
12/31/2019
72.89%
16Q
Load More
BUYBACK ANNOUNCEMENT(S) FOR CYMABAY THERAPEUTICS INC
LOADING...